Skip to content

Evaluation of the clinical efficacy of probiotic formula products in patients with atopic dermatitis

Evaluation of the clinical efficacy of probiotic formula products in patients with atopic dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092792
Enrollment
Unknown
Registered
2024-11-22
Start date
2024-05-24
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Probiotic formula:Take one sachet of probiotic products daily

Sponsors

The Peoples' Hospital of Tinghu District of Yancheng City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. meets the diagnosis of AD according to Hanfin and Rajka criteria; 2. 2 years <= age <= 80 years, male or female; 3. good compliance, able to comply with the requirements of the clinical trial; 4. atopic dermatitis assessment by a dermatologist with a SCORAD score of =25 (moderately severe); 5. subjects or guardians have signed the informed consent;

Exclusion criteria

Exclusion criteria: 1. Known hypersensitivity to any of the ingredients in the test drug; 2. patients who have received systemic glucocorticoid therapy within the week prior to the test or phototherapy (e.g., UVB, PUVA) that is suspected to be capable of affecting atopic dermatitis (eczema), or systemic therapy (immunosuppressive agents, cytosolic growth inhibitors); 3. Patients who are immunosuppressed (e.g., lymphoma) or have a history of malignant disease complicated by any dermatological condition that interferes with the evaluation of test results; 4. patients who refuse to sign the informed consent form or who are estimated to have poor compliance and poor likelihood of follow-up; 5. women during pregnancy or lactation; 6. recent (1-3 months) consumption of probiotic products or long-term consumption of yoghurt or probiotic drinks. 7. Recent (1-3 months) or long-term use of antibiotics. 8. Other cases that did not meet the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
dermatology life quality index, DLQI;SCORAD;Immunological indicators;

Secondary

MeasureTime frame
Fecal microbes;

Countries

China

Contacts

Public ContactWenwei Lu, Yanni Wang

Jiangnan University; People's Hospital of Tinghu, Yancheng

luwenwei@jiangnan.edu.cn+86 187 6269 1080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026